A 52-year-old woman with cirrhosis (Child-Pugh Class B, albumin 2.8 g/dL) is started on warfarin 5 mg daily for atrial fibrillation. Her INR at day 7 is 4.8 (therapeutic: 2–3). She has no signs of bleeding. Warfarin is highly protein-bound (99%) and metabolized by hepatic cytochrome P450. Which pharmacokinetic alteration best explains her excessive anticoagulation, and what is the most appropriate next step?

Explanation

## Warfarin Pharmacokinetics in Hepatic Cirrhosis **Key Point:** Warfarin's anticoagulant effect in cirrhosis is amplified by two converging pharmacokinetic changes: (1) reduced hepatic metabolism due to loss of functional hepatocytes and decreased P450 activity, and (2) increased free (unbound) warfarin concentration due to hypoalbuminemia. ### Protein Binding and Free Drug Concentration Warfarin is 99% protein-bound to albumin. In cirrhosis, serum albumin falls (here: 2.8 g/dL, normal >3.5), reducing the binding capacity: $$\text{Free drug fraction} = \frac{1}{1 + (f_u^{-1} - 1) \times \text{[Albumin]}}$$ **High-Yield:** Only the **free (unbound) fraction** is pharmacologically active. In hypoalbuminemia: - Total warfarin concentration may appear "normal" - But free warfarin concentration is **elevated** → excessive anticoagulation - This is why monitoring total drug levels is misleading; INR is the gold standard ### Hepatic Metabolism in Cirrhosis Warfarin is metabolized by hepatic CYP2C9 and CYP3A4. Cirrhosis causes: 1. **Loss of hepatic mass** → fewer enzyme-containing hepatocytes 2. **Decreased blood flow** through liver → reduced first-pass metabolism (if given orally) 3. **Reduced enzyme activity** → slower metabolism of warfarin **Clinical Pearl:** The combination of ↓ clearance + ↑ free fraction creates a **synergistic effect** — warfarin accumulates AND more of it is active. INR rises disproportionately to the dose. ### Comparison: Cirrhosis vs. Normal Liver | Parameter | Normal Liver | Cirrhosis | |-----------|--------------|----------| | Albumin | >3.5 g/dL | <3.0 g/dL | | Warfarin protein binding | 99% | 98–99% (lower) | | Free warfarin % | ~1% | ~2–3% | | Hepatic CYP450 activity | Normal | ↓ 30–50% | | Warfarin clearance | 0.13 mL/kg/min | ↓ 0.06–0.09 mL/kg/min | | Half-life | 40 hours | 60–80 hours | | INR response to 5 mg | Therapeutic (2–3) | Supratherapeutic (4.8) | **Mnemonic:** **CHIP** = Cirrhosis Has Impaired Protein synthesis (↓ albumin) and Impaired Pharmacokinetics (↓ metabolism). Both ↑ warfarin effect. ### Management of Supratherapeutic INR (4.8, No Bleeding) ```mermaid flowchart TD A[INR 4.8, No bleeding]:::outcome --> B{INR level?}:::decision B -->|4.5–10, no bleeding| C[Hold warfarin 1–2 days]:::action C --> D[Recheck INR in 2–3 days]:::action D --> E[Resume at lower dose]:::action B -->|>10 or bleeding| F[Give vitamin K 2.5–5 mg IV/PO]:::urgent F --> G[Consider FFP or PCC if life-threatening]:::urgent ``` **Correct Next Step:** 1. **Reduce warfarin dose** (from 5 mg to ~2–3 mg daily) 2. **Monitor INR closely** (recheck in 2–3 days) 3. **Educate patient** on bleeding precautions 4. **Avoid NSAIDs, aspirin, and other P450 inhibitors** — they will further increase INR [cite:Harrison 21e Ch 140; KD Tripathi 8e Ch 26]